Related Experiment Video

Updated: Jun 3, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K

Anticancer properties of histone deacetylase inhibitors - what is their potential?

Kajetan Kiełbowski1,2, Agata Szwedkowicz1, Paulina Plewa1

  • 1Department of Physiology, Pomeranian Medical University, Szczecin, Poland.

Expert Review of Anticancer Therapy
|January 10, 2025
PubMed
Abstract

Insights

Histone deacetylase (HDAC) inhibitors show promise in cancer treatment. Combining these epigenetic drugs with other therapies may improve patient outcomes and enhance cancer cell sensitivity to treatments.

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Oncology

Background:

  • Histone modifications, including acetylation, are key epigenetic regulators of gene expression.
  • Histone deacetylases (HDACs) control histone acetylation, influencing gene transcription.
  • Targeting histone acetylation has emerged as a viable strategy in cancer therapy, with several HDAC inhibitors approved.

Purpose of the Study:

  • To review the anticancer efficacy of approved and novel HDAC inhibitors.
  • To explore the potential of HDAC inhibitors in combination cancer therapies.

Main Methods:

  • A comprehensive literature review was performed.
  • Studies were identified using the PubMed database.
  • The review focused on evaluating the anticancer efficacy of HDAC inhibitors.

Main Results:

  • Evidence suggests HDAC inhibitors are effective anticancer agents.
  • Combining HDAC inhibitors with other anticancer agents shows promising benefits.
  • HDAC inhibitors may enhance cancer cell sensitivity to chemotherapy and targeted therapies.

Conclusions:

  • HDAC inhibitors represent a significant therapeutic avenue in oncology.
  • Combination therapies involving HDAC inhibitors warrant further investigation.
  • Future research should optimize combination strategies for improved efficacy and safety.
Keywords:
Histone deacetylase inhibitorHistone modificationsanticancer therapycancerpersonalised treatment

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K
Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

21.2K

Related Concept Videos

Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
404
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.2K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K